Apexigen Announces Presentation of Phase 2 Clinical Data on CD40 Antibody Sotigalimab at the SITC 2021 Annual Meeting

SAN CARLOS, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, today announced three upcoming poster presentations at the 36th Society for Immunotherapy of Cancer’s (SITC) Annual Meeting, to be held in...

Click to view original post